April 30, 2026
Regeneron Q1 2026 net income falls 10% to $727m
Regeneron Pharmaceuticals has reported GAAP [Generally Accepted Accounting Principles] net income of $727m for the first quarter of 2026 (Q1 2026), down 10% from $809m in Q1 2025.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







